|
Hazard ratios of dying from breast cancer in relation to use of menopausal hormone therapy |
||||
| Breast cancer deaths/exposed (n) |
Mortality ratea |
Hazard ratio (95% confidence interval)b |
Hazard ratio (95% confidence interval)c |
|
|
|
||||
| Never use |
230/1,491 |
1.9 |
1.0 (reference) |
1.0 (reference) |
| Current used |
46/477 |
1.1 |
0.55 (0.40 to 0.77) |
0.63 (0.42 to 0.95) |
| By duration |
||||
| <5 years |
28/216 |
1.5 |
0.73 (0.48 to 1.13) |
0.76 (0.45 to 1.27) |
| ≥ 5 years |
18/260 |
0.8 |
0.42 (0.26 to 0.68) |
0.52 (0.29 to 0.93) |
| By regimen |
||||
| Estrogen-progestin |
37/391 |
1.1 |
0.54 (0.37 to 0.77) |
0.59 (0.38 to 0.91) |
| Estrogen alone |
8/80 |
1.1 |
0.59 (0.29 to 1.20) |
0.78 (0.34 to 1.80) |
| Past usee |
34/219 |
1.9 |
1.01 (0.71 to 1.45) |
1.03 (0.68 to 1.54) |
| By duration |
||||
| <5 years |
25/155 |
1.9 |
1.04 (0.69 to 1.58) |
1.02 (0.64 to 1.63) |
| ≥ 5 years |
9/64 |
1.7 |
0.94 (0.48 to 1.83) |
1.02 (0.48 to 2.17) |
|
Observations with missing information on menopausal hormone therapy, recent mammography, tumor size, or lymph node involvement excluded. aBreast cancer deaths per 100 person-years. bAdjusted for age at diagnosis (5-year categories), recent mammography (yes/no). cAdjusted for age at diagnosis (5-year categories), recent mammography (yes/no), adjuvant endocrine therapy (yes/no) and adjuvant chemotherapy (yes/no), tumor size, and lymph node involvement. dLast use <6 months before diagnosis. eLast use at least 6 months before diagnosis. | ||||
Rosenberg et al. Breast Cancer Research 2008 10:R78 doi:10.1186/bcr2145 |
||||